Evidence map›Paper›PMID 35019674›Full record

ArticleMicrobiology spectrum2022

Recombinant Myeloperoxidase as a New Class of Antimicrobial Agents.

Zehong Cao, Guangjie Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zehong CaoDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama School of Medicine, Birmingham, Alabama, USA.
Guangjie ChengDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama School of Medicine, Birmingham, Alabama, USA.ORCID 0000-0002-9368-379X
University of Alabama at Birmingham · US

Funding

The Roles of LPS-Binding Protein Vascular Peroxidase-1 in Innate ImmunityR01AI141724 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHENG, GUANGJIE · 2019 to 2022
$1.5M
VPO1 Protects from Endotoxin-Mediated Inflammation and Septic ShockR21AI139900 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHENG, GUANGJIE · 2019 to 2020
$358k
NIAID NIH HHS R01 AI141724NIAID NIH HHS R21 AI139900
6 · The paper itself

Abstract

Heme-containing peroxidases are widely distributed in the animal and plant kingdoms and play an important role in host defense by generating potent oxidants. Myeloperoxidase (MPO), the prototype of heme-containing peroxidases, exists in neutrophils and monocytes. MPO has a broad spectrum of microbial killing. The difficulty of producing MPO at a large scale hinders its study and utilization. This study aimed to overexpress recombinant human MPO and characterize its microbicidal activities

Indexed as

Acute DiseaseAnimalsAnti-Infective AgentsCandida albicansDrug Resistance, BacterialEscherichia coliFemaleHEK293 CellsHumansHydrogen PeroxideMaleMethicillin-Resistant Staphylococcus aureusMiceMice, Inbred C57BLPeroxidasePneumonia, BacterialAnti-Infective AgentsHydrogen PeroxidePeroxidaseRecombinant Proteinsanimal modelsantimicrobial activityHEK293 cellsmyeloperoxidaserecombinant-protein productiontherapy

Identifiers

PMID35019674
PMCPMC8754140
OpenAlexW4206158237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.